1 Course: Ethnicity and Disease Biology: African-Americans and Other Minority Populations in MS Track: Comprehensive Care The 2014 Annual Meeting of the CMSC and the Sixth Cooperative Meeting with ACTRIMS May 28-May 31, 2014 Dallas, Texas Multiple Sclerosis in African-Americans Omar Khan, MD Professor & Chair, Department of Neurology Director, Sastry Foundation Advanced Imaging Laboratory Director, Multiple Sclerosis Center Wayne State University School of Medicine, Detroit
17
Embed
Course: Ethnicity and Disease Biology: African-Americans ...€¦ · 1 Course: Ethnicity and Disease Biology: African-Americans and Other Minority Populations in MS Track: Comprehensive
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Course: Ethnicity and Disease Biology: African-Americans and Other Minority Populations in MS
Track: Comprehensive Care
The 2014 Annual Meeting of the CMSC and the Sixth Cooperative Meeting with
ACTRIMSMay 28-May 31, 2014
Dallas, Texas
Multiple Sclerosis in African-Americans
Omar Khan, MDProfessor & Chair, Department of Neurology
Director, Sastry Foundation Advanced Imaging LaboratoryDirector, Multiple Sclerosis Center
Wayne State University School of Medicine, Detroit
2
Objectives
• Clinical characteristics of multiple sclerosis in African-Americans
• MRI investigations of multiple sclerosis in African-Americans
• Retinal structure injury in African-Americans with multiple sclerosis
• CSF humoral and other environmental features related to African-Americans with multiple sclerosis
Retinal Structure Injury in African-Americans with MS
AA-MS (n=61) vs CAU-MS (n=89)
Chorostecki et al., AAN 2014
Chorostecki et al., AAN 2014
Sub-Analysis: AA-MS (n=50) vs CAC-MS (n=68)(Without History of Optic Neuritis)
P<0.0001
AA-MS
CAU-MS
12
Sub-Analysis: AA-MS (n=50) vs CAC-MS (n=68)(Without History of Optic Neuritis)
p=0.004
p=0.0004
Chorostecki et al., AAN 2014
AA MS CSF IgG Index: 1.35 + 0.62Caucasian MS CSF IgG Index: 1.05 + 0.55, (p=0.001)
13
n African-Americans
n Caucasians P-value
Wash Univ Study CSF IgG Index
66 1.35 0.62 132 1.05 0.55 0.001
Wayne State UnivStudy CSF IgGIndex
150 1.50 + 0.86 150 1.08 + 0.88 <0.0001
Elevated African-American CSF IgG Index B-cell Humoral Response
Khan et al., 2009
SCC p value
CSF IgG Index & Time to EDSS 6.0
African-Americans
-0.41 0.002
Caucasians 0.004 0.96
Combined -0.54 <0.0001
500 600 700 800
Gray Matter Vol (ml)
1.00
2.00
3.00
4.00
5.00
6.00
IgG
ind
ex
CSF Humoral Response and Gray Matter Volume
Spearman Correlation Coefficient-0.565 (p=0.001)
Whole Group (n=196)
Spearman Correlation Coefficient -0.836
(P=0.0001)
Spearman Correlation Coefficient -0.018
(p=ns)
n=104 n=92
Khan et al., 2009
14
Brain (2007), 130, 1089-1104
Perivascular cuffing a white matter phenomenon. Rarely seen in the gray Khan et al.
WCN 2009
Phase ImagingCourtesy: BruceTrapp
15
Cortical Enhancing Lesions in African-Americans with MS
African-Americans
(n=92)
Caucasians (n-104)
P-value
% of Patients with Cortical Enhancing
Lesions29.7% 2.8% 0.0005
CSF IgG Index 1.50 + 0.86 1.08 + 0.88 <0.0001
Correlation between CSF IgG Index &
Cortical Enhancing Lesions
0.58 0.21<0.0001;<0.0001
Khan et al. WCN 2009
16
HSG: High-school GraduateCG: College Graduate
DA: Disease Awareness
African-Americans (n=150) Caucasians (n=150)
Level of Education, Awareness, and Disease Severity
Ramesh and Khan, WSU GRS 2012
Klineova S, Nicholas J, Walker A.Response to disease modifying therapies in African Americans with multiple sclerosis. Ethn Dis 2012;22:221-5
Cree BA, Al-Sabbagh A, Bennett R, Goodin D.Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol2005;62:1681-3
Cree BA, Stuart WH, Tornatore CS, Jeffery DR, Pace AL, Cha CH. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data.Arch Neurol 2011;68:464-8
Response to Disease Modifying Therapy
17
Summary & Future Directions• Several studies indicate greater disability, CNS tissue injury, and sub-optimal response to therapy in African-Americans than Caucasians with MS.
• Quantitative MRI studies, retinal structure injury (OCT), and CSF studies suggest differences in disease biology.
• Prospectively designed multi-centered studies are warranted to examine the differences between African-Americans and Caucasians with MS including response to therapy.
• Studies must include impact of education, health awareness, and access to health care as covariates that may affect disease severity and outcomes